Systematic Review and Meta-Analysis of Metabolic Changes Linked to Sacubitril/Valsartan Therapy - Takeaways - MDSpire

Systematic Review and Meta-Analysis of Metabolic Changes Linked to Sacubitril/Valsartan Therapy

  • By

  • Amir Parsa Abhari

  • Parastesh Rezvanian

  • Ali Reza Rahmani

  • Mohammad Fakhrolmobasheri

  • Fouad Meraji Far

  • Negar Ostadsharif

  • Farzad Adelparvar

  • February 9, 2026

  • 0 min

Share

  • 1

    Sacubitril/valsartan is an ARNI approved for heart failure, showing benefits in reducing mortality and hospital admissions.

  • 2

    The therapy has expanded indications for heart failure with mildly reduced and preserved ejection fraction.

  • 3

    Sacubitril/valsartan may influence metabolic parameters, including glycemic control and lipid metabolism.

  • 4

    This systematic review aims to clarify the metabolic profile of sacubitril/valsartan in patients with cardiometabolic comorbidities.

  • 5

    The study employs PRISMA guidelines and assesses metabolic indices through a comprehensive literature search.

Original Source(s)

Systematic Review and Meta-Analysis of Metabolic Changes Linked to Sacubitril/Valsartan Therapy

  • by Amir Parsa Abhari, Parastesh Rezvanian, Ali Reza Rahmani, Mohammad Fakhrolmobasheri, Fouad Meraji Far, Negar Ostadsharif, Farzad Adelparvar

  • February 9, 2026

Related Content

Role of psychological resilience and psychological distress in linking fear of disease progression to quality of life in chronic heart failure: a cross-sectional serial mediation analysis

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Prognostic value of CTI for major adverse cardiovascular events in patients With ST-elevation myocardial infarction after primary percutaneous coronary intervention